Multiple sclerosis (MS), a chronic autoimmune disease affecting the central nervous system, has long puzzled researchers with its complex etiology. A landmark 2013 study published in Nature Genetics marked a pivotal moment in multiple sclerosis genetics by identifying 48 new susceptibility variants associated with MS risk. This discovery, led by the International Multiple Sclerosis Genetics Consortium (IMSGC) with significant contributions from Australian and New Zealand scientists through the ANZgene consortium, nearly doubled the known genetic factors at the time, bringing the total to over 100 loci. The findings underscored the autoimmune nature of MS, particularly in its relapsing-remitting form, and highlighted overlaps with other immune disorders.

In Australia, where MS prevalence has surged to 37,756 cases as of 2025—a 77% increase since 2010—these genetic insights hold particular relevance. With an economic burden exceeding $3 billion annually, understanding genetic risk factors is crucial for advancing prevention, diagnosis, and treatment strategies tailored to the local population.

The 2013 IMSGC Study: Methods and Scale

The study leveraged the ImmunoChip, a custom genotyping array targeting immune-related loci, to analyze 14,498 MS cases and 24,091 controls in the discovery phase. Replication involved prior genome-wide association study (GWAS) data from 14,802 cases and 26,703 controls, totaling 80,094 individuals of European ancestry. Statistical rigor included association testing and Bayesian fine-mapping, confirming 48 new variants (P < 5 × 10^-8), three after conditioning on known signals.

Australian researchers, including David Booth, Graeme Stewart from Westmead Millennium Institute, and others from Florey Institute, University of Melbourne, Menzies Research Institute Tasmania, and more, contributed substantially via ANZgene, providing 1,800 local samples. This collaboration, initiated in 2005 and funded by MS Research Australia, has been instrumental in MS genetics globally. Read the full paper here.

Key Findings: 48 New Variants and Immune Pathways

The variants mapped to 103 loci outside the major histocompatibility complex (MHC), implicating pathways like T-cell activation, cytokine signaling, and antigen presentation. Fine-mapping pinpointed five regions where single variants explained over 50% of the signal. Notably, many overlapped with loci for Crohn's disease, celiac disease, and type 1 diabetes, suggesting shared autoimmune mechanisms.

• Strongest non-MHC signals in immune genes like IL2RA and CD40, previously identified by ANZgene.
• Confirmation of vitamin D-related CYP27B1, linking environmental factors to genetics.
• Evidence for relapsing-remitting MS as primarily autoimmune-driven.

These discoveries refined polygenic risk models, where hundreds of common variants each contribute modestly to overall risk.

Australian Contributions Through ANZgene

The ANZgene consortium, coordinating over 3,500 DNA samples from Australia and New Zealand, played a key role. Earlier, it identified CD40 and CYP27B1 in 2009 (Nature Genetics) and contributed to confirming 57 risk genes in 2011 (Nature). By 2026, ANZgene leads next-generation sequencing with Regeneron, analyzing exomes from 3,000+ cases/controls to uncover rare variants in progressive MS. Learn more about ANZgene.

Institutions like Westmead, Florey, Menzies Tasmania, and Flinders University exemplify Australia's leadership in MS genetics research.

MS Landscape in Australia: Prevalence and Burden

Australia has one of the highest MS prevalences globally at 139.2 per 100,000 (2025 data), with hotspots in Tasmania (200.6 per 100,000) and Victoria (173.7). Incidence trends contribute to this rise, alongside better diagnosis and longevity. The 2025 MS Prevalence Report by MS Australia notes 62% on disease-modifying therapies (DMTs), yet costs per person range from $42,688 (no disability) to $135,780 (severe), totaling $3 billion—driven 28% by lost productivity. Access the full 2025 report.

Photo by Artem Beliaikin on Unsplash

Pathophysiological Insights from Genetic Discoveries

The 48 variants reinforced MS as an immune-mediated disease, with non-coding changes altering gene regulation in immune cells. For instance, variants near IL12RB2 affect cytokine pathways central to inflammation. Step-by-step, GWAS identify associations, fine-mapping resolves causal variants, functional studies (e.g., CRISPR editing) link to biology, and polygenic risk scores (PRS) quantify individual risk.

In MS, PRS incorporating 200+ variants explain ~30% heritability, aiding prognosis. Australian studies like UTAS's 2026 work on genetic mimics use PRS to differentiate MS from similar conditions.

Building on 2013: Recent Australian Advances

Post-2013, IMSGC expanded to >233 variants by 2020, now >200 loci. In 2026, WEHI's Dr. Hamish King, funded $400k by MS Australia, develops platforms to test >100 variants' combined effects on immune cells. UniSA's Dr. David Stacey (2025) pioneers PRS for pre-symptomatic risk, linking to EBV. These build directly on 2013 foundations. WEHI breakthrough details.

Implications for Diagnosis and Personalized Medicine

While single variants don't predict MS, PRS stratify risk—high scorers monitored post-EBV infection. In Australia, with EBV nearly universal, PRS could flag at-risk youth. Trials integrate PRS for DMT selection; e.g., variants predict interferon-beta response.

• Early detection via blood-based PRS + EBV serology.
• Tailored therapies targeting variant-affected pathways (e.g., BTK inhibitors).
• Risk prediction for families, informing lifestyle interventions like vitamin D.

Treatment Horizons and Drug Repurposing

Genetic overlaps enable repurposing: e.g., Crohn's drugs like ustekinumab trialed in MS. Australian-led trials test pathway inhibitors. Future: gene editing for high-risk variants, though ethical hurdles remain.

Challenges: From Variants to Therapies

Non-coding variants complicate causality; functional validation needed. Polygenicity demands large samples; Australia's ANZgene exemplifies collaboration. Environmental interactions (EBV, smoking, low vitamin D) modulate genetics—vital for Australia's sunny climate paradox.

Photo by REGINE THOLEN on Unsplash

Future Outlook: Towards Prevention

By 2030, PRS + biomarkers may enable prevention trials. MS Australia's $60m+ investment drives this. Global efforts like IMSGC continue, with Australia pivotal via ANZgene's sequencing.